Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet Dose-Ranging in Primary HPT
NCT03774771Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 1998
- Primary completion
- Dec 1999
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cinacalcet in primary hyperparathyroidism (PHPT) (4 arms), sponsored by Amgen. Primary endpoint: Number of Participants with Adverse Events. Started Sep 1998; status: completed.
02
Drugs
cinacalcet
03
Conditions
primary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on NCT03774771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774771.